Werewolf Therapeutics (NASDAQ:HOWL) Trading Up 1% – What’s Next?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shares rose 1% during trading on Friday . The stock traded as high as $1.11 and last traded at $1.08. Approximately 149,182 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 437,833 shares. The stock had previously closed at $1.07.

Analyst Ratings Changes

HOWL has been the subject of several research analyst reports. Wedbush lowered their price objective on shares of Werewolf Therapeutics from $8.00 to $6.00 and set an “outperform” rating for the company in a report on Friday, May 9th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a report on Wednesday, March 12th.

Werewolf Therapeutics Stock Up 1.0%

The company’s 50-day moving average is $1.12 and its 200 day moving average is $1.19. The company has a market capitalization of $48.50 million, a PE ratio of -0.65 and a beta of 0.62. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.09 and a current ratio of 8.09.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.04. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Insider Activity at Werewolf Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 162,539 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The stock was purchased at an average cost of $0.98 per share, with a total value of $159,288.22. Following the completion of the acquisition, the director directly owned 6,237,482 shares of the company’s stock, valued at approximately $6,112,732.36. This trade represents a 2.68% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. MPM Asset Management LLC grew its position in shares of Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after acquiring an additional 25,688 shares during the period. MPM Bioimpact LLC lifted its position in Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares in the last quarter. Geode Capital Management LLC lifted its position in Werewolf Therapeutics by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 702,558 shares of the company’s stock valued at $1,040,000 after purchasing an additional 16,569 shares in the last quarter. Northern Trust Corp grew its holdings in Werewolf Therapeutics by 7.3% during the fourth quarter. Northern Trust Corp now owns 244,390 shares of the company’s stock valued at $362,000 after purchasing an additional 16,640 shares during the period. Finally, Bridgeway Capital Management LLC grew its holdings in Werewolf Therapeutics by 24.4% during the fourth quarter. Bridgeway Capital Management LLC now owns 109,586 shares of the company’s stock valued at $162,000 after purchasing an additional 21,500 shares during the period. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.